Treatment Strategies: When GVHD Happens

When GVHD occurs, the goal of treatment is to quiet the donor immune system enough to protect your organs while still allowing it to fight any remaining cancer and infections. Treatment is often a “stepped” process, moving from broad medications to more targeted therapies.

First-Line Treatment: The Standard Starting Point

The current standard of care for both acute and chronic GVHD is corticosteroids (such as methylprednisolone or prednisone) ^[1][2]. These are powerful anti-inflammatory drugs that work quickly to dampen the immune response across the entire body.

What to Expect from Steroids

While highly effective, high-dose and long-term steroids come with significant side effects that can be as challenging as the GVHD itself. It is critical to know what to expect and how your team will manage it:

• Severe Infection Risk: Steroids drastically lower your immune response. You will likely be prescribed prophylactic (preventative) antibiotics, antivirals, and antifungal medications.
• Physical Changes: You may experience weight gain, swelling in the face (“moon face”), and bone density loss ^[1]. Your doctor may prescribe calcium and Vitamin D to protect your bones.
• Metabolic Impact: Steroids can cause high blood sugar (hyperglycemia) ^[1]. Even if you are not diabetic, you may need insulin temporarily.
• Emotional Toll: Expect mood swings, irritability, and severe insomnia. This is a chemical reaction, not a personal failing. Sleep aids and emotional support are valid and necessary interventions.

Moving to Second-Line: “Steroid-Refractory” GVHD

In some cases, steroids alone are not enough. Your medical team may describe your GVHD as steroid-refractory (or glucocorticoid-refractory) if ^[1][3]:

• Symptoms continue to get worse after 3 to 5 days of high-dose steroids.
• Symptoms do not improve after 7 to 14 days.
• GVHD returns as soon as the steroid dose is lowered.

If this happens, it is not a failure on your part. It simply means the “flash fire” of the immune response requires a more specific “extinguisher.”

The Paradigm Shift: Targeted Therapies

In recent years, treatment has shifted from broad immune suppression to targeted therapies that block specific biological pathways. When discussing these, ask your doctor what baseline tests (like blood counts or liver panels) you need before starting.

1. Ruxolitinib (Jakafi)

Ruxolitinib is now considered the standard second-line treatment for both acute and chronic steroid-refractory GVHD ^[4][5]. It works by inhibiting JAK1 and JAK2, two proteins that act like “on-switches” for inflammation.

• Efficacy: In major trials like REACH3, ruxolitinib showed significantly higher response rates and better symptom control compared to older “best available” therapies ^[6][7].
• Monitoring: While effective, it requires close monitoring for low blood counts and viral reactivations (like CMV) ^[8][9].

2. New Options for Chronic GVHD

If ruxolitinib is not sufficient, or if chronic GVHD involves specific issues like skin scarring, other recently approved options include:

• Belumosudil (Rezurock): A ROCK2 inhibitor that helps rebalance the immune system and has “anti-fibrotic” properties, meaning it may help reduce the scarring or thickening of the skin and other organs ^[10][11].
• Axatilimab: A monoclonal antibody that targets the CSF-1 receptor. It specifically targets the cells (macrophages) that drive inflammation and scarring in chronic GVHD ^[12][13].

3. Organ-Specific and Emerging Treatments

• Vedolizumab: This is a “gut-selective” therapy. It blocks T cells from entering the gastrointestinal tract, making it a potential option for patients with severe gut-focused acute GVHD ^[14][15].
• ECP (Extracorporeal Photopheresis): A procedure where your blood is treated with light and then returned to you. It is often used as a “gentle” second-line option that doesn’t further weaken the overall immune system ^[16][17].

Clinical Trials: Accessing Tomorrow’s Care

Clinical trials are often a vital part of the treatment journey, especially for steroid-refractory disease. These studies offer access to novel cellular therapies or new drug combinations. For example, the RLS-0071 trial [NCT06343792] is currently investigating a new treatment for hospitalized patients with acute GVHD who have not responded to steroids. Your team can help you determine if a trial is the right next step for you.